Table 1 Demographic and baseline characteristics
Pateclizumab | ADA | Placebo | All patients | |
|---|---|---|---|---|
(n = 85) | (n = 85) | (n = 44) | (n = 214) | |
Age (yr) | ||||
Mean (SD) | 50.2 (13.1) | 50.6 (13.3) | 48.8 (14.0) | 50.1 (13.3) |
Median | 51.0 | 52.0 | 48.5 | 51.0 |
Range (min, max) | 18-75 | 20-73 | 23-75 | 18-75 |
Age group | ||||
<65 yr (%) | 72 (84.7%) | 69 (81.2%) | 36 (81.8%) | 177 (82.7%) |
≥65 yr (%) | 13 (15.3%) | 16 (18.8%) | 8 (18.2%) | 37 (17.3%) |
Sex | ||||
Female | 78 (91.8%) | 68 (80.0%) | 37 (84.1%) | 183 (85.5%) |
Male | 7 (8.2%) | 17 (20.0%) | 7 (15.9%) | 31 (14.5%) |
Race | ||||
White | 53 (62.4%) | 48 (56.5%) | 29 (65.9%) | 130 (60.7%) |
Black | 1 (1.2%) | 0 (0.0%) | 0 (0.0%) | 1 (0.5%) |
American Indian or Alaska Native | 1 (1.2%) | 3 (3.5%) | 0 (0.0%) | 4 (1.9%) |
Asian | (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Native Hawaiian or other Pacific Islander | (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Not available | 30 (35.3%) | 34 (40.0%) | 15 (34.1%) | 79 (36.9%) |
Region | ||||
US and Western Europe | 12 (14.1%) | 12 (14.1%) | 6 (13.6%) | 30 (14.0%) |
Latin America and Eastern Europe | 73 (85.9%) | 73 (85.9%) | 38 (86.4%) | 184 (86.0%) |
BMI (kg/m2) | ||||
Mean (SD) | 27.114 (5.075) | 27.309 (4.194) | 26.903 (5.547) | 27.148 (4.830) |
Weight (kg) | ||||
Mean (SD) | 68.66 (14.88) | 69.52 (12.75) | 69.15 (22.61) | 69.11 (15.96) |